Manuel S Yepes

US Patent:

7235529, Jun 26, 2007

Filed:

Jan 7, 2004

Appl. No.:

10/752041

Inventors:

Timothy A. Coleman - Gaithersburg MD, US
Daniel A. Lawrence - Derwood MD, US
Manuel Yepes - Alexandria VA, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD
The Regents of the University of Michigan - Ann Arbor MI

International Classification:

A61K 38/57
A61K 39/00
C07K 14/47
C12P 21/06

US Classification:

514 12, 514 2, 530350, 4241921, 4241841, 4241851, 435 691

Abstract:

The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.

US Patent:

7375076, May 20, 2008

Filed:

May 20, 2004

Appl. No.:

10/849540

Inventors:

Daniel A. Lawrence - Derwood MD, US
Manuel S. Yepes - Rockville MD, US
Dudley Strickland - Brookeville MD, US

Assignee:

The Regents of The University of Michigan - Ann Arbor MI

International Classification:

A61K 38/00

US Classification:

514 2

Abstract:

The present invention is a method of reducing vascular permeability in tissue of a subject comprising inhibiting the activity of serine proteinase tissue-type plasminogen activator (tPA). This tPA activity which increases permeability of the tissue in a subject results in edema in the tissue is separate from tPA's thrombolytic activity. The present invention more specifically relates to administering an amount of a tPA inhibitor sufficient to reduce the vascular permeability increasing activity of tPA in a subject. Useful tPA inhibitors for the present method are neuroserpin, mutant neuroserpin, wild-type PAI-1, mutant PAI-1, an antibody that binds to tPA, an antibody that binds to the low-density lipoprotein (LDL) receptor or a low-density lipoprotein (LDL) receptor family antagonist.

US Patent:

7939490, May 10, 2011

Filed:

Nov 8, 2005

Appl. No.:

11/718786

Inventors:

Jeffrey A. Winkles - Frederick MD, US
Manuel S. Yepes - Atlanta GA, US

Assignee:

University of Maryland, Baltimore - Baltimore MD

International Classification:

A61K 39/44
A61K 39/395
A61K 38/16
A61K 38/18
A61P 25/00

US Classification:

514 11, 4241331, 4241341, 4241411, 4241431, 4241451, 4241781, 514 76, 514 122, 514 133, 514 177, 514 212

Abstract:

The present invention is directed to compositions and methods for treating cerebral edema and cell death in neurological conditions characterized by disruption of the architecture of the neurovascular unit with increase in the permeability of the NVU, particularly for treating stroke. One aspect of the present invention relates to a composition comprising an agent that interferes with a TWEAK-mediated signaling pathway. Another aspect of the present invention relates to a method of using a composition which comprises an agent that inhibits Fn14 activity or Fn14 expression for the prevention and/or treatment of cerebral edema and cell death occurring in certain neurological conditions such as cerebral ischemia.

US Patent:

8147828, Apr 3, 2012

Filed:

Apr 17, 2007

Appl. No.:

11/736499

Inventors:

Ulf Eriksson - Stockholm, SE
Daniel Lawrence - Ann Arbor MI, US
Enming Joe Su - Ann Arbor MI, US
Dudley Strickland - Brookeville MD, US
Manuel Yepes - Atlanta GA, US
Linda Fredriksson - Hagersten, SE

Assignee:

Ludwig Institute for Cancer Research - New York NY
University of Maryland - Baltimore MD
The Regents of the University of Michigan - Ann Arbor MI

International Classification:

A61K 39/395
C07K 16/28
C07K 14/71

US Classification:

4241301, 4241431, 5303871, 53038822

Abstract:

Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-α antagonist.

US Patent:

20020143165, Oct 3, 2002

Filed:

Sep 21, 2001

Appl. No.:

09/957485

Inventors:

Daniel Lawrence - Derwood MD, US
Manuel Yepes - Alexandria VA, US
Maria Sandkvist - Derwood MD, US
Michael Wong - Wexford PA, US
Timothy Coleman - Gaithersburg MD, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

C07H021/02
C07H021/04

US Classification:

536/023100

Abstract:

The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had a stroke.

US Patent:

20020165147, Nov 7, 2002

Filed:

Nov 13, 2001

Appl. No.:

09/987021

Inventors:

Manuel Yepes - Alexandria VA, US
Daniel Lawrence - Derwood MD, US
Timothy Coleman - Gaithersburg MD, US

International Classification:

A61K038/17
C07H021/04
C12P021/02
C12N005/06
C07K014/435

US Classification:

514/012000, 530/350000, 536/023500, 435/069100, 435/320100, 435/325000

Abstract:

The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.

US Patent:

20040038880, Feb 26, 2004

Filed:

Jan 31, 2003

Appl. No.:

10/355208

Inventors:

Daniel Lawrence - Derwood MD, US
Manuel Yepes - Alexandria VA, US
Maria Sandkvist - Derwood MD, US
Timothy Coleman - Gaithersburg MD, US
Michael Wong - Wexford PA, US

International Classification:

A61K038/17

US Classification:

514/012000

Abstract:

The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had a stroke.

US Patent:

20070259806, Nov 8, 2007

Filed:

Jun 4, 2007

Appl. No.:

11/757481

Inventors:

Gregg Hastings - Westlake Village CA, US
Timothy Coleman - Derwood MD, US
Patrick Dillon - Carlsbad CA, US
Daniel Lawrence - Derwood MD, US
Maria Sandkvist - Ann Arbor MI, US
Manuel Yepes - Rockville MD, US
Michael Wong - East Amhurst NY, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD
The Regents of the University of Michigan - Ann Arbor MI

International Classification:

A61K 38/00
C07H 21/04
C07K 14/00
C07K 16/18
C12N 15/00
C12N 15/87
C12N 5/06
C12P 1/04
G01N 33/53

US Classification:

514002000, 435320100, 435325000, 435326000, 435466000, 435069100, 435007100, 530350000, 530387100, 530388100, 536022100

Abstract:

The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.